drugset / Trial / NCT00269984

A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer

NCT00269984

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and effectiveness of epoetin alfa versus placebo, injected beneath the skin, in the treatment of patients with persistent anemia caused by advanced cancer, with a below normal hematocrit of \<= 37%. Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.

Timeline

Start
Primary completion
Completion
1990-06

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 100 iu/kg Subcutaneous
Subject epoetin alfa Protein / enzyme biologic 150 iu/kg Subcutaneous

Indications